Literature DB >> 32240363

Lymph-node Epstein-Barr virus concentration in diagnosing cervical lymph-node metastasis in nasopharyngeal carcinoma.

HuiFang Li1, Can Huang1,2, Qiuyan Chen3, Chuan Peng1, Rong Zhang4, Jingxian Shen4, Mingyuan Chen3, Haiqiang Mai5, Ruhai Zou6.   

Abstract

PURPOSE: Cervical lymph-node (CLN) metastasis commonly occurs in patients with nasopharyngeal carcinoma (NPC) metastasis. The presence of Epstein-Barr virus (EBV) genomes in neck lymph nodes may diagnose CLN. This research was designed to appraise the diagnostic value of EBV concentration for cervical lymph nodes in NPC.
METHODS: Two hundred and fifty-three NPC patients with 276 CLNs were enrolled. MRI was performed to detect CLN metastasis, and plasma EBV concentration was measured by quantitative PCR before treatment. Ultrasonography (US) and US-FNA were subsequently performed in the suspicious lymph nodes. Fifteen patients (22 lymph nodes) underwent fine-needle aspiration cytology (FNAC), and the remaining 242 patients (254 lymph nodes) underwent core needle biopsy (CNB) for CLNs at the clinician's demand. The aspiration needle was rinsed with 1 ml of normal saline for EBV detection. The method of lymph-node EBV measurement was consistent with that for plasma. The MRI results and EBV concentrations in plasma and lymph nodes were recorded and analyzed. Plasma EBV concentrations ≥ 4000 copies/ml were regarded as positive.
RESULTS: CLN-EBV concentrations ≥ 787.5 copies/ml were regarded as positive according to receiver-operating characteristic curve analysis. The AUC of the EBV (0.925) concentration in CLN metastasis was significantly larger than the AUC of MRI (0.714) (P < 0.001). The sensitivity and specificity were 94.09% and 48.72% for MRI in lymph-node metastasis and 95.36% (P > 0.05) and 84.62% (P < 0.01) for EBV DNA in CLN metastasis, respectively. The sensitivity and specificity of EBV in plasma were 77.2% and 71.8%, respectively. The diagnostic specificity and AUC of EBV in CLNs were higher than those of MRI and plasma EBV (P < 0.005).
CONCLUSIONS: Ultrasound-guided CLN FNA to obtain EBV concentrations may provide a new method to diagnose CLN metastasis with high sensitivity and specificity.

Entities:  

Keywords:  Cervical lymph-node metastasis; Epstein–Barr virus; Fine-needle aspiration; Lymph-node metastasis; Nasopharyngeal carcinoma

Mesh:

Year:  2020        PMID: 32240363     DOI: 10.1007/s00405-020-05937-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  10 in total

1.  Fine-needle aspiration cytology of metastatic nasopharyngeal carcinoma.

Authors:  José M Viguer; José A Jiménez-Heffernan; Pilar López-Ferrer; Marcos Banaclocha; Blanca Vicandi
Journal:  Diagn Cytopathol       Date:  2005-04       Impact factor: 1.582

2.  Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Authors:  Anthony T C Chan; Y M Dennis Lo; Benny Zee; Lisa Y S Chan; Brigette B Y Ma; Sing-Fai Leung; Frankie Mo; Maria Lai; Stephen Ho; Dolly P Huang; Philip J Johnson
Journal:  J Natl Cancer Inst       Date:  2002-11-06       Impact factor: 13.506

3.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

4.  Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.

Authors:  Sing-fai Leung; Benny Zee; Brigette B Ma; Edwin P Hui; Frankie Mo; Maria Lai; K C Allen Chan; Lisa Y S Chan; Wing-hong Kwan; Y M Dennis Lo; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

5.  How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography?

Authors:  Xin-Biao Liao; Yan-Ping Mao; Li-Zhi Liu; Ling-Long Tang; Ying Sun; Yan Wang; Ai-Hua Lin; Chun-Yan Cui; Li Li; Jun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

6.  Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US.

Authors:  P Vassallo; K Wernecke; N Roos; P E Peters
Journal:  Radiology       Date:  1992-04       Impact factor: 11.105

7.  Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods.

Authors:  Janaki Abeynayake; Ryan Johnson; Paolo Libiran; Malaya K Sahoo; Hongbin Cao; Raffick Bowen; K C Allen Chan; Quynh-Thu Le; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2014-07-30       Impact factor: 5.948

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  The feasibility analysis of omission of elective irradiation to level IB lymph nodes in low-risk nasopharyngeal carcinoma based on the 2013 updated consensus guideline for neck nodal levels.

Authors:  Xiaomin Ou; Yibing Miao; Xiaoshen Wang; Jianhui Ding; Xiayun He; Chaosu Hu
Journal:  Radiat Oncol       Date:  2017-08-18       Impact factor: 3.481

Review 10.  Review of ultrasonography of malignant neck nodes: greyscale, Doppler, contrast enhancement and elastography.

Authors:  M Ying; K S S Bhatia; Y P Lee; H Y Yuen; A T Ahuja
Journal:  Cancer Imaging       Date:  2014-01-06       Impact factor: 3.909

  10 in total
  1 in total

1.  Cullin 4A/protein arginine methyltransferase 5 (CUL4A/PRMT5) promotes cell malignant phenotypes and tumor growth in nasopharyngeal carcinoma.

Authors:  Xiuying Sun; Jinhui Zhou; Zhicun Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.